8-KEarnings & ResultsRegulation FDExhibits & Filings

Cencora, Inc. 8-K Report, Financial Results (Feb 4, 2026)

Filed February 4, 2026For Securities:COR

Summary

Cencora, Inc. (COR) has filed a Form 8-K to disclose significant events occurring around the end of January and early February 2026. The most impactful news for investors is the company's acquisition of a majority stake in OneOncology for approximately $4.6 billion in cash, funded by new debt. This strategic move is expected to integrate OneOncology's operations into Cencora's U.S. Healthcare Solutions segment, signaling an expansion in the oncology physician services platform. Additionally, the filing announces the release of Cencora's earnings for the fiscal quarter ended December 31, 2025, with details provided in an attached news release. Investors should pay close attention to the financial performance reported for this quarter and the strategic implications of the OneOncology acquisition, particularly its impact on the company's debt structure and future growth within the U.S. Healthcare Solutions segment.

Key Highlights

  • 1Cencora, Inc. acquired a majority stake in OneOncology, a national platform for independent oncology practices, for approximately $4.6 billion in cash.
  • 2The acquisition was funded through new debt financing.
  • 3OneOncology's results will be consolidated into Cencora's U.S. Healthcare Solutions reportable segment.
  • 4The company announced its earnings for the fiscal quarter ended December 31, 2025, via a news release filed as an exhibit.
  • 5A conference call and webcast are scheduled for February 4, 2026, to discuss Q4 2025 results and related matters.

Frequently Asked Questions

The acquisition of a majority stake in OneOncology represents a significant expansion for Cencora into the physician-led oncology platform space. It is expected to strengthen Cencora's U.S. Healthcare Solutions segment by integrating a national network of independent oncology practices, potentially enhancing its service offerings and market position in this specialized area.

Cencora funded the approximately $4.6 billion cash consideration for the OneOncology acquisition through new debt financing. Investors should review the upcoming financial reports for details on the increased debt levels and their impact on the company's leverage and interest expenses.

Details regarding Cencora's financial results for the fiscal quarter ended December 31, 2025, are provided in a news release filed as Exhibit 99.1 to this Form 8-K. Additionally, the company is hosting a conference call and webcast on February 4, 2026, to discuss these results and related matters.

Yes, OneOncology's future operating results will be consolidated as a component of Cencora's U.S. Healthcare Solutions reportable segment. This integration is a key strategic move and investors should monitor the performance and contribution of this segment going forward.